Association for Molecular Pathology v. Myriad Genetics, Inc.
GPTKB entity
Properties (31)
| Predicate | Object |
|---|---|
| gptkbp:caseTypes |
12-398
|
| gptkbp:community_engagement |
advocacy for patient rights
|
| gptkbp:court |
gptkb:Supreme_Court_of_the_United_States
|
| gptkbp:date |
2013
June 13, 2013 |
| gptkbp:decidedBy |
gptkb:United_States_Supreme_Court
|
| https://www.w3.org/2000/01/rdf-schema#label |
Association for Molecular Pathology v. Myriad Genetics, Inc.
|
| gptkbp:impact |
healthcare_access
healthcare_legislation |
| gptkbp:influenced |
future patent cases
|
| gptkbp:involves |
gene patenting
|
| gptkbp:judges |
gptkb:Justice_Scalia
patent law |
| gptkbp:legal_principle |
intellectual property rights
natural phenomena |
| gptkbp:legal_representation |
gptkb:American_Civil_Liberties_Union
patent validity |
| gptkbp:legalStatus |
intellectual property law
monopolization of genetic information U.S._patent_system |
| gptkbp:notableFeature |
biotechnology industry
Supreme_Court_decisions |
| gptkbp:outcome |
genetic research
expanded access to genetic testing invalidated gene patents |
| gptkbp:politicalParty |
gptkb:Justice_Thomas
|
| gptkbp:precedent |
patent eligibility
Myriad decision |
| gptkbp:related_to |
biomedical ethics
|
| gptkbp:relatedPatent |
Association_for_Molecular_Pathology_v._United_States_Patent_and_Trademark_Office
|
| gptkbp:significance |
impact on genetic testing
|